The debate over prescription drug costs keeps circling the same ground: more calls for transparency, more government mandates, more scrutiny of pharmacy benefit managers, or PBMs. It comes from an und ...
The challenges facing the U.S. healthcare system may be complex, but for many states, finding a villain to blame has been easy: simply point the finger at private equity. Over the past two years, stat ...
The FDA advisory committee's recent vote against Capricor Therapeutics' cell therapy for Duchenne muscular dystrophy looked like a decision about one product. It may ultimately be remembered as somet ...
FDA's advisory committee process is one of the agency's greatest institutional strengths. No other major drug regulator conducts scientific advisory meetings as publicly -- or as visibly -- as FDA. Sc ...
Congress has a responsibility to fix policy mistakes when they become clear, especially when those mistakes could make it harder for patients to receive life-saving treatments in their local communiti ...
In May, I wrote about the emergence of a bootleg market for retatrutide, Eli Lilly's experimental obesity drug. The problem was already hard to miss. Websites and wellness businesses were sellin ...
Somewhere in America today, a patient is waiting for a treatment that does not yet exist. A family is waiting for a miracle. And thanks to extraordinary advances in biotechnology, a breakthrough may b ...
The world recently minted its first trillionaire, and the inevitable refrain afterward was clear - tax him However, taxing Elon Musk to fund anything chosen by the government is a waste of productivit ...
Here is how Washington influence can work: The founder of a kratom company and entities associated with his business make major political contributions, secure access to senior officials, and lobby th ...
Last November, President Trump stood in the Oval Office beside executives from Eli Lilly and Novo Nordisk and promised America's seniors more affordable weight-loss drugs. The delivery vehicle is the ...